SK pharmteco

About SK pharmteco

SK pharmteco supports all analytical requirements for pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), Cell and Gene Therapy (CGT), and formulated drug products. From Analytical Method Development and Implementation to Analytical Method Validation and stability, SK pharmteco is fully equipped with fully compliant CGMP instrumentation geared toward product analysis and product release. SK pharmteco supports spectroscopy, chromatography, particle size distribution, calorimetry, osmolality, mass spectrometry, and ICH Stability project requirements. 

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • US
  • 2022
    On CPHI since
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Primary activities
Analytical Services
API Producer
Chemical Development
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Intermediates Manufacturer
Laboratory Services
View company profile
Contact info
  • +353 1 8139227
  • Website
  • 12460 Akron Street, Suite 100,, 95742, Rancho Cordova,, California, United States
Show contact info Hide contact info
Meet us at

CPHI Frankfurt 2025

Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Products from SK pharmteco (1)

  • Analytical Services

    Product Analytical Services

    • Method Development & Validation • Release Testing • Reference Standard Qualification • Compendial Testing (USP / EP / BP / JP) • Characterization (XRPD, NMR, FTIR) • Chiral Separations • Particle Size Analysis • Elemental Impurities (ICP-MS) USP ,, ICH Q3D • Impurity Identification (GC-MS & High-Resolut...

SK pharmteco Resources (1)

  • Empowering API Manufacturing: Perspectives From a Contract Development and Manufacturing Organization

    Video Empowering API Manufacturing: Perspectives From a Contract Development and Manufacturing Organization

    As a Contract Development and Manufacturing Organization (CDMO), navigating the landscape of EU API manufacturing presents critical challenges and opportunities. In response to Cefic’s November 2023 recommendations, CDMOs have an important role to play to foster sustainable growth, support reshoring initiatives, and drive innovation investment to prioritize supply security and social-environmental standards. The decline in EU-based API production underscores the urgency to address competitive pressures from global markets and EU regulatory dynamics. This presentation examines the implications for CDMOs, offering insights into strategies to strengthen API manufacturing capabilities, enhance global competitiveness, and contribute to healthcare resilience.
    2024-10-23